Founder’s Vision
ANKTIVA
BCG
Our Science
Careers
Contact
Patients & Caregivers
ANKTIVA®
Clinical Trials
Patients
Therapeutic Areas
Bladder Cancer
Glioblastoma
HIV
Human Papillomavirus
Lymphopenia
Lynch Syndrome
Non-Hodgkin Lymphoma
Non-Small Cell Lung Cancer
Ovarian Cancer
Healthcare Providers
ANKTIVA®
Clinical Trials
Trial Investigators
Expanded Access
Researchers
Platforms & Modalities
Trial Investigators
Cell Licensing
Publications
Our Company
About
Pipeline
Contact
Compliance & Transparency
News and Events
Investors
Select Page
Acceptance Requirements
Adult patients diagnosed with CD19 and CD20-positive B-cell non-Hodgkin lymphoma
Have completed two lines of chemotherapy
Search for:
Recent Posts
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device
World Conference on Lung Cancer
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy
ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients
